Neuroendocrine tumors, including small cell lung cancer and neuroendocrine prostate cancer, are very aggressive with high chances of spreading.
Cytokinetics CEO defends Royalty Pharma deal: ‘That narrative was hijacked’
Cytokinetics CEO Robert Blum blamed investor frustration over a deal with Royalty Pharma on a “hijacked” narrative that the company would be better off selling